There are 2949 resources available
295P - Physiologically based pharmacokinetic (PBPK) modeling of the central nervous system (CNS) pharmacokinetics of tucatinib in patients with breast cancer brain metastasis
Presenter: Anthony Lee
Session: E-Poster Display
Resources:
Abstract
296P - Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
Presenter: Leisha Emens
Session: E-Poster Display
Resources:
Abstract
297P - SP142 immunohistochemistry (IHC) PD-L1 inter- and intra-pathologist agreement in triple negative breast carcinoma (TNBC)
Presenter: Jia-Min Pang
Session: E-Poster Display
Resources:
Abstract
298P - Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis
Presenter: Silvia González Martínez
Session: E-Poster Display
Resources:
Abstract
299P - MicroRNAs related to immune response as markers in the prognosis of metastatic breast cancer
Presenter: Sofia Agelaki
Session: E-Poster Display
Resources:
Abstract
300P - Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
Presenter: Emma Zattarin
Session: E-Poster Display
Resources:
Abstract
301P - Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
Presenter: Yen-Shen Lu
Session: E-Poster Display
Resources:
Abstract
302P - Utility of lymphocyte-monocyte ratio (LMr) for predicting progression free survival (PFS) in patients with HR+/HER2- metastatic breast cancer (MBC) treated with palbocilcib + fulvestrant as first-line therapy
Presenter: Lucrezia Raimondi
Session: E-Poster Display
Resources:
Abstract
303P - Use of CA 15.3 for the detection of secondary metastatic breast cancer
Presenter: Lore De Cock
Session: E-Poster Display
Resources:
Abstract
304P - ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial
Presenter: Jean-Sebastien Frenel
Session: E-Poster Display
Resources:
Abstract